TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23901264
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + IFN‐α and IFN‐γ (1.5 million IU of each) 3 times per week (group D)
Study: 7782031
Drug: Recombinant a2
Normalized name: PROCYANIDIN A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant a2 interferon (Roferon) 6 MU x 7 days every 3 weeks, Adriamycin 60 mg/m2 i.v. once every 3 weeks, Tamoxifen 10 mg p.o. twice daily continuously, Desferrioxamine 500 mg i.m. daily x 7 days every 3 weeks, Ascorbic acid 300 mg p.o. daily 1 hour after DFO x 7 days every 3 weeks
Study: 2236463
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate maintenance doses (600 mg to 1,500 mg/day)
Study: 346191
Drug: Fluorescent antibody
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorescent antibody method for detection of estrogen receptors
Study: 25960116
Drug: PFJ-targeted exercise,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFJ-targeted exercise, education, manual-therapy and taping program
Study: 24057079
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (group I) with 1 intravaginal ovule containing 30 mcg estriol and Lactobacilli acidophili (50 mg lyophilisate containing at least 100 million live bacteria) once daily for 2 weeks, then two ovules once weekly for a total of 6 months plus pelvic floor rehabilitation.
Study: 24057079
Drug: Intravaginal estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal estriol ovule (1 mg) plus pelvic floor rehabilitation (group II).
Study: 23247908
Drug: Crushed IRO‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed IRO‐A (15 mg)
Study: 23247908
Drug: Crushed IRO
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed IRO (15 mg)
Study: 12455823
Drug: Pool exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pool exercise therapy and education
Study: 11270999
Drug: Domestic 5-isosorbide
Normalized name: hydralazine
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Domestic 5-isosorbide mononitrate (5-IM) sustained-release capsule, 50 mg, single and 5-day repeated doses
Study: 11270999
Drug: Imported 5-isosorbide
Normalized name: hydralazine
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imported 5-isosorbide mononitrate (5-IM) sustained-release capsule, 50 mg, single and 5-day repeated doses
Study: 11270999
Drug: Both domestic
Normalized name: domestic cow dander extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both domestic and imported capsules
Study: 1478035
Drug: Acipimox (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (250 mg three times daily for 3 months)
Study: 26599983
Drug: Nonselective β-blockers
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonselective β-blockers (NSBBs)
Study: 24943829
Drug: Usual health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual health classes including drug education
Study: 17451612
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy/meditation intervention (4 one-hour sessions)
Study: 17451612
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list control (3 months before receiving treatment)
Study: 12424105
Drug: Intravenous 2
Normalized name: Premarin Intravenous 25 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 2 mg/kg of [13C]Phe
Study: 1714885
Drug: Flecainide 150
Normalized name: flecainide 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide 150 mg twice daily
Study: 30875313
Drug: NP (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP (no cavity preparation, control)
Study: 30875313
Drug: MOD3 (3.0-mm-deep
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOD3 (3.0-mm-deep MOD preparation, not restored)
Study: 30875313
Drug: MOD3R (3.0-mm-deep
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOD3R (3.0-mm-deep MOD preparation restored with RBC)
Study: 30875313
Drug: MOD5 (5.0-mm-deep
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOD5 (5.0-mm-deep MOD preparation, not restored)
Study: 30875313
Drug: MOD5R (5.0-mm-deep
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOD5R (5.0-mm-deep MOD preparation restored with RBC)
Study: 30875313
Drug: MOD3RC (3.0-mm-deep
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOD3RC (3.0-mm-deep MOD preparation restored with RBC and subjected to mechanical cycling)
Study: 30875313
Drug: MOD5RC (5.0-mm-deep
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOD5RC (5.0-mm-deep MOD preparation restored with RBC and subjected to mechanical cycling)
Study: 29191194
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine (HM) services utilization
Study: 27614789
Drug: Intralipid (2mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid (2mL diluted at 20% in 250mL saline) infusion
Study: 27614789
Drug: Saline (250mL)
Normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (250mL) infusion
Study: 22562540
Drug: 10% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% lidocaine topical spray
Study: 22562540
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water topical spray
Study: 20165986
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy comprising intravenous application of platinum and paclitaxel
Study: 16273808
Drug: Finnish RA
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Finnish RA Combination Therapy Trial (FIN-RACo)
Study: 12421195
Drug: Dopexamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopexamine (1 micro g. kg‐1. min‐1) continuously after induction of anesthesia until 18 h after CPB
Study: 12421195
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of bupivacaine 0.25% [(body height (cm) - 100). 10-1=ml.h-1] for the whole study period
Study: 18211117
Drug: Cinnarizine 20
Normalized name: cinnarizine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine 20 mg and dimenhydrinate 40 mg three times daily for 4 weeks
Study: 18211117
Drug: Betahistine 12
Normalized name: betahistine 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 12 mg three times daily for 4 weeks
Study: 16608150
Drug: Real beer
Normalized name: BEER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real beer (mean breath alcohol concentration of .115 g%)
Study: 12915338
Drug: Levetiracetam 1000
Normalized name: levetiracetam 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam 1000 to 3000 mg/day
Study: 10789176
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia with sponge anesthesia and intraocular injection of 0.15 ml lidocaine 1%
Study: 10789176
Drug: Peribulbar injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peribulbar injection of 6 ml Xylonest 2%
Study: 8795476
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine patch (Transderm, 0.05 mg/h)
Study: 10399774
Drug: Placebo skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo skin patch
Study: 30905926
Drug: Insulin group
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin group
Study: 26952590
Drug: 20-mg oral
Normalized name: istradefylline 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg oral d-amphetamine
Study: 23396551
Drug: Traditional anti-hypertensive
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional anti-hypertensive therapy (Control)
Study: 22125196
Drug: Capsule Endoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule Endoscopy Crohn's Disease Activity Index (CECDAI)
Study: 11994349
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg DNG
Study: 11994349
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg DNG
Study: 11994349
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg DNG
Study: 9705044
Drug: Amlodipine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (up to 10 mg)
Study: 9705044
Drug: Lisinopril (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (up to 20 mg)
Study: 9705044
Drug: Both Amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Amlodipine and Lisinopril
Study: 2142292
Drug: fenoterol after
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenoterol after a prior single administration of prednisone
Study: 688256
Drug: cis‐dichlorodiammineplatinum(II) (P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis‐dichlorodiammineplatinum(II) (P) at a dose of 15 mg/m2/day by iv push on Days 1‐5 every 4 weeks, followed by cyclophosphamide (C) at a dose of 400 mg/m2 and adriamycin (A) at a dose of 40 mg/m2 upon progression or renal toxic effects.
Study: 688256
Drug: C‐A (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: C‐A (cyclophosphamide and adriamycin) at a dose of 400 mg/m2 and 40 mg/m2 respectively, given by iv push on Day 1 every 4 weeks.
Study: 688256
Drug: CAP‐I (C‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP‐I (C‐A plus concurrent P at 40 mg/m2 by IV push on Day 1 every 4 weeks).
Study: 28923098
Drug: Baricitinib +
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baricitinib + MTX (4 mg once daily + MTX administered once weekly)
Study: 15848574
Drug: EC‐MPS 720
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC‐MPS 720 mg b.i.d. (equimolar to MMF 1000 mg b.i.d.)
Study: 15848574
Drug: EC‐MPS 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC‐MPS 450 or 432 mg/m2 b.i.d. for children
Study: 15848574
Drug: MMF (<
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF (< or =1000 mg b.i.d.)
Study: 11888226
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine 5 microg/kg followed by 0.3 microg/kg per hour infusion
Study: 11888226
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine 3 microg/kg followed by 0.3 microg/kg per hour infusion
Study: 11888226
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine 2 microg/kg followed by 0.3 microg/kg per hour infusion
Study: 11888226
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% bolus and continuous infusion
Study: 11888226
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (all doses)
Study: 9498511
Drug: Splanchnic/antioxidant therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Splanchnic/antioxidant therapy (folate, mannitol, low-dose isoproterenol)
Study: 9498511
Drug: Splanchnic/antioxidant therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Splanchnic/antioxidant therapy group
Study: 18475395
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of doxycycline
Study: 353464
Drug: Silymarin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (2 sugar-coated tablets 70 mg three times daily)
Study: 18986845
Drug: Sclerosant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerosant therapy
Study: 18986845
Drug: Bolus followed
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus followed by continuous-infusion proton pump inhibitor
Study: 15562880
Drug: Sublingual swallow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual swallow immunotherapy with ragweed allergen extract
Study: 11566454
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone treatment (6 mg/day)
Study: 7821475
Drug: Amethocaine cream
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amethocaine cream
Study: 3076791
Drug: Subcutaneous terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous terbutaline (continuous infusion and 6‐hourly divided dose regimens)
Study: 29071556
Drug: Probucol combined
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probucol combined with hydration (probucol 500 mg twice daily and hydration)
Study: 17609022
Drug: Trichloracetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichloracetic acid or podophyllin 25% (single therapy)
Study: 15625221
Drug: Educational video
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational video about the consent process in treatment research
Study: 9462166
Drug: Alpha-tocopherol (Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol (Vitamin E) 600 mg twice a day for 12 weeks
Study: 7949636
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of cisapride (5 mg)
Study: 7949636
Drug: Oral cisapride
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cisapride (15 mg TID) for 14 days
Study: 7949636
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of cisapride (5 mg) after 14 days of treatment
Study: 31690049
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg/kg/bm)
Study: 25727442
Drug: Varenicline tablets
Normalized name: Varenicline Tablets
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline tablets
Study: 23843980
Drug: Gatifloxacin regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin regimen (for drug-resistant patients)
Study: 23843980
Drug: Control regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control regimen (for drug-resistant patients)
Study: 19346845
Drug: Sublingual nitroglycerine
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerine (NTG)
Study: 16720918
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg, three times daily) and alpha-tocopherol (300 mg, twice daily) during radiotherapy, followed by 400 mg of PTX and 300 mg of alpha-tocopherol daily for 3 months after radiotherapy
Study: 11743460
Drug: Sepragel sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sepragel sinus (hylan B gel)
Study: 28741390
Drug: Low maternal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low maternal haemoglobin level (<130 g/L) in the first trimester
Study: 28741390
Drug: High maternal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High maternal haemoglobin level (≥130 g/L) in the second trimester
Study: 25179587
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1200 mg, twice daily, added to contingency management
Study: 21939972
Drug: Continuous lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous lateral rotational therapy (CLRT) for 5 days
Study: 22554721
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg the night before surgery)
Study: 17633371
Drug: Shenqi Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Fuzheng Injection (SQFZI), 250 mL via intravenous dripping starting from 5 days before operation and after ending CPB once a day.
Study: 9870832
Drug: Fluconazole 400
Normalized name: fluconazole 400 MG in 200 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 400 mg orally daily
Study: 8205374
Drug: Flogan (potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flogan (potassium diclofenac suspension)
Study: 8205374
Drug: Cataflam (potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cataflam (potassium diclofenac suspension)
Study: 2488496
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D 4,000 IU per day
Study: 2488496
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of ergocalciferol 600,000 IU every six months
Study: 2488496
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of at least 1 g per day
Study: 2488496
Drug: Parenteral ergocalciferol
Normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral ergocalciferol
Study: 1096276
Drug: Prenazone 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenazone 600 mg daily
Study: 31286828
Drug: Combined (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined (active rTMS + fluoxetine)
Study: 31286828
Drug: Placebo (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham rTMS + placebo fluoxetine)
Study: 31286828
Drug: Fluoxetine (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (sham rTMS + fluoxetine)
Study: 25653511
Drug: Alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 10 mg monotherapy
Study: 25653511
Drug: Alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 10 mg + antihypertensive combination therapy
Study: 21046285
Drug: AMG 114
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 114 (15 μg)
Study: 21046285
Drug: AMG 114
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 114 (50 μg)
Study: 21046285
Drug: AMG 114
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 114 (200 μg)
Study: 8641482
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist (GnRH-a) and oral contraceptive (OC) therapy
Study: 3902531
Drug: Naproxen 1000
Normalized name: naproxen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 1000 mg once daily
Study: 23219537
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg avanafil
Study: 23219537
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg avanafil
Study: 17007488
Drug: V.A.C. Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: V.A.C. Therapy
Study: 10977030
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin powder (87.2 U)
Study: 10977030
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin (10.2 U)
Study: 10977030
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin (5.5 U)
Study: 8485067
Drug: Nicorandil 10
Normalized name: nicorandil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 10 mg bid
Study: 3959099
Drug: Ongoing daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing daily self-monitoring
Study: 24311644
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 1125 mg
Study: 24311644
Drug: Pregabalin (PGB)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin (PGB) 294 mg
Study: 23892777
Drug: Varenicline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (0.5 mg/day for first 3 days, then 1 mg/day for 4 days)
Study: 21958943
Drug: E2/NETA (estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/NETA (estradiol 2 mg/norethisterone acetate 1 mg)
Study: 18434919
Drug: Fluoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine treatment for pediatric major depressive disorder
Study: 10717926
Drug: Vobenzim (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vobenzim (initial dose 18‐24 dragees, maintenance 12‐15 dragees a day)
Study: 10717926
Drug: Pathogenetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pathogenetic therapy only (Control)
Study: 8263606
Drug: High fiber
Normalized name: High Fiber Gummies Soft Chew
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fiber diet (31.3 g fiber/d, 586 mg calcium/d)
Study: 8263606
Drug: Low fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fiber diet (6.5 g fiber/d, 530 mg calcium/d)
Study: 3744131
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (5,000 antifactor Xa U/24 h)
Study: 3744131
Drug: Low-dose conventional
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose conventional heparin (5,000 IU/12 h)
Study: 24121658
Drug: G.O.A.L. intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: G.O.A.L. intervention (90-min after-school physical activity club 4 days/week and one motivational interviewing session with a registered nurse)
Study: 24121658
Drug: G.O.A.L. intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: G.O.A.L. intervention
Study: 15723201
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 100% tea tree oil (TTO)
Study: 15723201
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 5% TTO lotion
Study: 15723201
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of placebo lotion (no TTO)
Study: 15723201
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 100% macadamia oil